The Cooper Companies, Inc. (COO) is a global medical device maker best known for its CooperVision contact-lens business and its CooperSurgical women's-health and fertility unit. After the company reported fiscal third-quarter results in early September, the stock fell sharply, dropping from the low $60s to near $54 — within a few dollars of its 52-week low of $51.01.
That decline has reframed the conversation around the stock. Investors who once debated whether COO could reclaim $90 are now asking a more modest but still meaningful question: can it recover to $75? That level sits near the top of the current analyst price-target range and represents a substantial, multi-month recovery rather than a quick bounce.
The pullback was driven by a classic "beat on earnings, miss on sales" dynamic. Cooper reported adjusted earnings per share (EPS) of about $1.15, slightly ahead of consensus, but revenue of roughly $1.07 billion came in below expectations of about $1.10 billion. Management attributed the softness in part to U.S. channel destocking and inventory reductions pressuring CooperVision, while also trimming its full-year EPS guidance to a range of $4.51 to $4.55.
Compounding the disappointment, the company completed a strategic review of CooperSurgical but concluded that shareholders were better served by continued ownership than by a sale. Some investors had anticipated a value-unlocking transaction, and the "no deal" outcome added to the selling pressure. The stock's market capitalization now stands near $10.3 billion.
Following the earnings report, several firms lowered their targets, leaving a wide spread. Recent actions include Mizuho maintaining an Outperform rating with a $75 target, Jefferies holding a Buy with a $70 target, and Needham setting a Buy at $73, while J.P. Morgan, Citi, and Baird moved to more cautious positions with targets of roughly $58 to $61. The broader consensus rating sits at "Hold," with average price targets clustering in the mid-$60s to low-$70s.
This matters for the $75 question: the target is not wildly aggressive — it is essentially in line with the more optimistic end of current Street thinking. That said, reaching it still implies roughly 38% appreciation, which would require fundamentals to reaccelerate rather than merely stabilize.
Several factors could support a recovery. First, the board authorized an expanded share-repurchase program of $3 billion, equivalent to a meaningful portion of outstanding shares, which can support EPS per share and signals management's confidence that shares are undervalued.
Second, the fertility franchise within CooperSurgical remains a structurally attractive growth driver, supported by long-term demographic trends toward later-in-life childbearing and improving reimbursement. Third, Cooper's myopia-management portfolio, including the MiSight lens, has been a bright spot and holds long-term expansion potential as awareness of pediatric myopia grows.
Finally, valuation has compressed sharply. With the stock near $54 and forward earnings expectations in the mid-$4 range, the multiple has fallen well below the company's historical averages, providing a potential foundation for multiple expansion if growth concerns ease.
The path to $75 is not straightforward. CooperVision's momentum is the central concern: until destocking runs its course and daily-disposable lens growth reaccelerates, the top line may remain sluggish. Management's guidance cut and soft fourth-quarter outlook also suggest near-term visibility is limited.
Additionally, the decision not to divest CooperSurgical removes a potential near-term catalyst that some investors had priced in, and the emergence of securities-fraud investigation notices adds a layer of legal and sentiment-related uncertainty. If contact-lens growth stays weak, the stock could struggle to hold even its current level, let alone mount a 38% rally.
From a technical-analysis standpoint, the $51.01 52-week low is the critical support level to watch; a decisive break below it would signal further downside. On the way up, the stock would first need to reclaim the pre-earnings zone near $63, which now acts as an early resistance level, before challenging the broader $70–$75 area where the analyst consensus and the psychological round numbers converge. Reaching $75 would require clearing that overhead supply and establishing a durable higher-low structure.
For traders monitoring setups like COO, AI Daily Buy/Sell Signals offers a data-driven way to track changing conditions. The product uses artificial intelligence to continuously scan thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on evolving market behavior, technical patterns, and AI-driven analysis. Traders can use these signals to spot new opportunities, monitor existing positions, and identify shifting trends more efficiently. As sentiment around COO evolves, tools like this can help investors stay responsive to the next directional move.
At recent levels near $54, a move to $75 is possible but by no means assured. The strongest arguments in favor are a cheapened valuation, an aggressive buyback program, and durable long-term demand in fertility and myopia management. The primary risks are persistent CooperVision weakness, reduced guidance, and the absence of a strategic catalyst.
Investors should monitor whether channel destocking abates, whether contact-lens growth reaccelerates in coming quarters, and whether the company's repurchase activity provides a floor under the stock. Reaching $75 would likely require both an operational reacceleration and a meaningful re-rating — a combination that remains plausible but unproven in the near term.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, COO has been loosely correlated with BDX. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if COO jumps, then BDX could also see price increases.
| Ticker / NAME | Correlation To COO | 1D Price Change % |
|---|---|---|
| COO | 100% | +0.58% |
| Pharmaceuticals: Other industry (50 stocks) | 53% Loosely correlated | -0.31% |
| Pharmaceuticals industry (154 stocks) | 2% Poorly correlated | -1.52% |